A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
This study evaluated the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.
STUDY TYPE: HIV Prevention
DURATION: February 2015 - July 2018
STUDY DESIGN: Randomized, parallel assigned, quadrupal masked interventional study
POPULATION: Healthy volunteers aged 18 - 65 years old
NUMBER OF SITES: 8
SITE LOCATIONS: US, Brazil, Malawi, and South Africa